Loading organizations...
Carrick Therapeutics is a technology company.
Carrick Therapeutics has raised $155.0M across 2 funding rounds.
Carrick Therapeutics has raised $155.0M in total across 2 funding rounds.
Carrick Therapeutics is a clinical-stage biopharmaceutical company focused on building the future of oncological therapy to improve patient outcomes. Our extensive experience in developing innovative therapies allows us to deliver a novel best-in-class and first-in-class portfolio.
Carrick Therapeutics is a clinical-stage biopharmaceutical company specializing in oncology, developing first-in-class and best-in-class therapies targeting aggressive cancers to address unmet patient needs.[1][2] It builds an innovative portfolio of novel treatments, such as CDK7 and CDK12/13 inhibitors, serving cancer patients through partnerships with academics, contract research organizations, and licensors to advance drug discovery and clinical outcomes.[2][3][4]
The company operates from Dublin, Ireland, and Oxford, UK, with a focus on leveraging deep expertise in oncological therapy for improved patient results, actively seeking differentiated assets via licensing and collaborations.[1][3]
Carrick Therapeutics emerged as an oncology-focused biopharmaceutical venture, backed early by investors like Rosetta Capital, which highlights its roots in creating differentiated novel therapies for aggressive cancers.[1] While specific founding year and founders are not detailed in available sources, the company's leadership includes CEO Timothy Pearson, and it has evolved into a clinical-stage entity with a structured pipeline, management team, board, and science overview sections on its site.[1][4]
Pivotal early traction stems from building a portfolio through strategic partnering, including licensing assets and conducting studies with external experts, positioning it as a dedicated player in oncology innovation.[3]
Carrick Therapeutics rides the wave of precision oncology, where targeted therapies like CDK inhibitors disrupt traditional cancer treatment by hitting specific molecular drivers in aggressive forms.[1][4] Timing aligns with surging demand for differentiated assets amid rising cancer prevalence and advances in drug discovery partnerships, bolstered by market forces favoring biopharma firms with strong pipelines and collaborator networks.[2][3]
It influences the ecosystem by licensing opportunities and fostering collaborations, accelerating innovation from academia to clinic and contributing to a portfolio approach that de-risks oncology development.[3]
Carrick Therapeutics is poised to advance its CDK-focused pipeline through ongoing clinical trials, new licensing deals, and partnerships, potentially delivering breakthrough therapies for hard-to-treat cancers.[2][3][4] Trends like AI-aided drug discovery and combo therapies will shape its path, amplifying its role in oncology's evolution toward personalized medicine. As it scales, expect expanded influence via trial data readouts and investor engagement, solidifying its foundation for transformative patient impact—echoing its mission to build the future of oncological therapy.[2]
Carrick Therapeutics has raised $155.0M in total across 2 funding rounds.
Carrick Therapeutics's investors include ARCH Venture Partners, Cambridge Innovation Capital, Evotec, Google Ventures, Lightstone Ventures, Rosetta Capital, Woodford Investment Management, Cambridge Enterprise, Robert Tansley, Werner Lanthaler, Jason Lettmann.
Carrick Therapeutics has raised $155.0M across 2 funding rounds. Most recently, it raised $60.0M Series C in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $60.0M Series C | ARCH Venture Partners, Cambridge Innovation Capital, Evotec, Google Ventures, Lightstone Ventures, Rosetta Capital | |
| Oct 1, 2016 | $95.0M Series A | ARCH Venture Partners, Woodford Investment Management | Cambridge Enterprise, Robert Tansley, Werner Lanthaler, Google Ventures, Jason Lettmann |